Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000725572 | SCV000701026 | pathogenic | not provided | 2016-12-12 | criteria provided, single submitter | clinical testing | |
Counsyl | RCV000592803 | SCV000794153 | likely pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2017-09-16 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000725572 | SCV002016918 | pathogenic | not provided | 2020-08-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000592803 | SCV002252833 | pathogenic | Autosomal recessive limb-girdle muscular dystrophy type 2A | 2023-04-27 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 497002). This variant is also known as c.946-4_946-1del. Disruption of this splice site has been observed in individual(s) with autosomal recessive limb-girdle muscular dystrophy (PMID: 19556129; Invitae). This variant is present in population databases (rs766156798, gnomAD 0.006%). This sequence change affects a splice site in intron 6 of the CAPN3 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CAPN3 are known to be pathogenic (PMID: 10330340, 15689361). |